Federal Register / Vol. 72, No. 138 / Thursday, July 19, 2007 / Notices 39633 

have excess free radicals, and Tdp1 

repairs DNA damage by oxygen radicals. 

Applications and Modality: It is 

anticipated that Tdp1 inhibitors in 

association with Top1 inhibitors can 

have selective activity toward tumor 

tissues. Tdp1 inhibitors may exhibit 

antitumor activity by themselves 

because tumors have excess free 

radicals. 

Market: 600,000 deaths from cancer 

related diseases were estimated in 2006. 

In 2006, cancer drug sales were 

estimated to be $25 billion. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Yves Pommier et al. (NCI). 

Relevant Publication: A manuscript 

directly related to the above technology 

will be available as soon as it is 

accepted for publication. 

Patent Status: U.S. Provisional 

Application No. 60/921,980 filed 05 Apr 

2007 (HHS Reference No. E–130–2007/ 

0–US–01). 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Adaku 

Nwachukwu, J.D.; 301/435–5560; 

madua@mail.nih.gov. 

Collaborative Research Opportunity: 

The Center for Cancer Research, 

National Cancer Institute, Laboratory of 

Molecular Pharmacology is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize inhibitors of TyrosylDNA phosphodiesterase (Tdp1). Please 

contact John D. Hewes, Ph.D. at 301–

435–3121 or hewesj@mail.nih.gov for 

more information. 

Dated: July 9, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–13955 Filed 7–18–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552(b)(c)(6), Title 5 

U.S.C., as amended. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel, 

Expedited Review of Tornado Survivors 

PTSD. 

Date: July 31, 2007. 

Time: 4 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Allan F. Mirsky, PhD, 

Scientific Review Administrator, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Boulevard, Rm. 6157, MSC 

9609, Bethesda, MD 20892–9609, 301–496–

2551, afmirsky@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: July 9, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3507 Filed 7–18–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Special 

Emphasis Panel, Pathogenesis of NeuroAIDS 

and Alcohol Use (RFA–AA–07–015). 

Date: August 7, 2007. 

Time: 1:30 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Alcohol Abuse 

and Alcoholism, 5635 Fishers Lane, 

Rockville, MD 20852, (Telephone Conference 

Call). 

Contact Person: Abraham P. Bautista, PhD, 

Chief, Extramural Project Branch Review, 

National Institute on Alcohol Abuse & 

Alcoholism, National Institutes of Health, 

5635 Fishers Lane, RM 3039, Rockville, MD 

20852, 301–443–9737, 

bautistaa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Cinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants, 

National Institutes of Health, HHS) 

Dated: July 9, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3508 Filed 7–18–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Special 

Emphasis Panel, Review of Specialized and 

Comprehensive Alcohol Research Centers 

(RFA–AA–07–002; AA–02–003). 

Date: August 2, 2007. 

Time: 1:30 p.m. to 5 p.m. 


cprice-sewell on PROD1PC66 with NOTICES